Lactobacillus reuteri ( DrugBank: Lactobacillus reuteri )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	3
299	Cystic fibrosis	1

97. Ulcerative colitis

---

Clinical trials : 2,527 /  Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05118919 (ClinicalTrials.gov)	February 9, 2022	26/10/2021	A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis	A Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild to Moderate Ulcerative Colitis	Ulcerative Colitis	Biological: BGP-014;Biological: Placebo	BioGaia Pharma AB	NULL	Recruiting	18 Years	N/A	All	50	Phase 1/Phase 2	Sweden
2	EUCTR2019-004578-25-SE (EUCTR)	09/07/2021	27/12/2019	A clinical study in patients with mild to moderate ulcerative colitis to test the tolerability of Lactobacillus reuteri BGP-014	A randomised placebo-controlled safety study of Lactobacillus reuteri BGP-014 in patients with active mild to moderate ulcerative colitis	Mild to moderate ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: BGP-014 Capsules Product Code: BGP-014 INN or Proposed INN: Lactobacillus reuteri Other descriptive name: LACTOBACILLUS REUTERI	BioGaia Pharma AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 1;Phase 2	Sweden
3	NCT03798210 (ClinicalTrials.gov)	January 1, 2017	7/1/2019	Lactobacillus Reuteri ATCC PTA 4659 in Ulcerative Colitis	The Effect of Lactobacillus Reuteri ATCC PTA 4659 in Patients With Ulcerative Colitis	Ulcerative Colitis Flare	Dietary Supplement: Lactobacillus reuteri;Dietary Supplement: Placebo	Uppsala University	NULL	Recruiting	18 Years	80 Years	All	40	Phase 2	Sweden

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01737983 (ClinicalTrials.gov)	May 2009	12/7/2012	Effect of Lactobacillus Reuteri in Cystic Fibrosis	Lactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis.	CYSTIC FIBROSIS	Dietary Supplement: Lactobacillus reuteri;Dietary Supplement: placebo	Azienda Policlinico Umberto I	NULL	Completed	6 Years	42 Years	Both	61	Phase 4	Italy